Takeda Pharmaceutical (TKPHF) Net Income towards Common Stockholders (2017 - 2026)

Takeda Pharmaceutical's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$155.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 108.55% year-over-year to -$155.1 million; the TTM figure through Mar 2026 stood at $7.0 billion (down 11.29% YoY), while the FY2026 annual figure was $1.3 billion, up 79.8% from the prior year.
• Net Income towards Common Stockholders was -$155.1 million for Q1 2026 at Takeda Pharmaceutical, down from $913.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $4.7 billion in Q3 2025 to a low of -$155.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $1.3 billion across 5 years, with a median of $843.2 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders jumped 9009.04% in 2025, then plunged 108.55% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $843.2 million in 2022, then climbed by 27.73% to $1.1 billion in 2023, then slumped by 30.86% to $744.6 million in 2024, then climbed by 22.7% to $913.6 million in 2025, then plunged by 116.97% to -$155.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$155.1 million (Q1 2026), $913.6 million (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.